Covered recipient · General Payments record
KRISH PATEL
Allopathic & Osteopathic Physicians Internal Medicine Hematology & Oncology
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2025 · Entire year
$50,717.96
132 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2025 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Consulting Fee | $45,047.15 | 15 |
| Food and Beverage | $4,635.52 | 112 |
| Travel and Lodging | $1,035.29 | 5 |
By paying entity
PY2025 · entire year · sorted by reported total
Page 3 of 3; records 101–132 of 132 matching records. This page contains 32 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
KRISH PATEL
NPI 1346484821 · CMS profile ID 430197
Allopathic & Osteopathic Physicians / Internal Medicine / Hematology & Oncology
NASHVILLE, TN
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 3 of 3; records 101–132 of 132 matching records. This page contains 32 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1346484821?year=2025&recipient=provider&page=3#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- KRISH PATEL, NPI 1346484821, CMS profile ID 430197. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 3; records 101–132 of 132 matching records. This page contains 32 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1346484821?year=2025&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
- APA 7
- IndustryPayments. (2026). KRISH PATEL, NPI 1346484821, CMS profile ID 430197. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 3; records 101–132 of 132 matching records. This page contains 32 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1346484821?year=2025&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
- Bluebook
- KRISH PATEL, NPI 1346484821, CMS profile ID 430197, IndustryPayments, General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 3 of 3; records 101–132 of 132 matching records. This page contains 32 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e. https://industrypayments.org/provider/npi-1346484821?year=2025&recipient=provider&page=3#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2025 · Physicians and non-physician practitioners · CMS publication 2026-06-30
132 matching records · $50,717.96 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 101–132 of 132.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| Genentech USA, Inc. | $16.00 | 04/08/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1211532101 | CMS |
| PFIZER INC. | $17.76 | 04/07/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1229062994 | CMS |
| Eli Lilly and Company | $81.76 | 04/05/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1186704081 | CMS |
| Teleflex LLC | $21.13 | 04/02/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1242450210 | CMS |
| PUMA BIOTECHNOLOGY, INC. | $14.97 | 03/25/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1251741596 | CMS |
| Adaptive Biotechnologies Corporation | $101.57 | 03/24/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1254936825 | CMS |
| Daiichi Sankyo Inc. | $25.71 | 03/24/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1197054773 | CMS |
| Janssen Biotech, Inc. | $19.29 | 03/17/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1174895946 | CMS |
| Novocure Inc. | $16.07 | 03/07/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1251151029 | CMS |
| Blueprint Medicines Corporation | $42.32 | 03/02/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1235810668 | CMS |
| Lilly USA, LLC | $23.03 | 02/27/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1186704083 | CMS |
| Kite Pharma, Inc. | $93.55 | 02/22/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1212089801 | CMS |
| ABBVIE INC. | $126.75 | 02/21/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1203508289 | CMS |
| ADC THERAPEUTICS AMERICA, INC. | $15.70 | 02/21/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1246122472 | CMS |
| ADC THERAPEUTICS AMERICA, INC. | $44.09 | 02/20/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1246122522 | CMS |
| BeiGene USA, Inc. | $82.01 | 02/20/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1202882352 | CMS |
| Secura Bio, Inc. | $128.06 | 02/20/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1193370813 | CMS |
| Kite Pharma, Inc. | $43.94 | 02/14/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1212089799 | CMS |
| ADC THERAPEUTICS AMERICA, INC. | $36.37 | 02/12/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1246126005 | CMS |
| Kite Pharma, Inc. | $117.75 | 02/11/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1212089803 | CMS |
| Regeneron Healthcare Solutions, Inc. | $31.49 | 02/03/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1213008727 | CMS |
| ARRAY BIOPHARMA INC | $21.65 | 01/31/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1231133669 | CMS |
| Stemline Therapeutics Inc. | $24.16 | 01/30/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1244097346 | CMS |
| Daiichi Sankyo Inc. | $24.17 | 01/29/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1197046553 | CMS |
| Merck Sharp & Dohme LLC | $24.81 | 01/28/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1238251527 | CMS |
| Genentech USA, Inc. | $21.82 | 01/23/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1211532095 | CMS |
| Exelixis Inc. | $18.60 | 01/21/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1218797493 | CMS |
| Eli Lilly and Company | $1,200.00 | 01/14/2025 | Consulting Fee | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1186687171 | CMS |
| Janssen Biotech, Inc. | $18.97 | 01/14/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1174882468 | CMS |
| ABBVIE INC. | $85.17 | 01/10/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1203508283 | CMS |
| PharmaEssentia USA Corporation | $18.20 | 01/08/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1246825406 | CMS |
| AstraZeneca Pharmaceuticals LP | $18.57 | 01/07/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1206213447 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
- Source files
- Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Recipient | $4,326.59 | 4 |
| PY2025 | Principal investigator | $1,096,951.53 | 61 |
| PY2024 | Principal investigator | $2,837,665.11 | 238 |
| PY2023 | Recipient | $1,600.00 | 3 |
| PY2023 | Principal investigator | $2,255,623.12 | 182 |
| PY2022 | Recipient | $1,880.00 | 2 |
| PY2022 | Principal investigator | $2,058,436.91 | 98 |
| PY2021 | Principal investigator | $1,704,415.97 | 132 |
| PY2020 | Principal investigator | $2,628,950.77 | 126 |
| PY2019 | Recipient | $476.00 | 1 |
| PY2019 | Principal investigator | $1,071,506.45 | 84 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
65 records in PY2025
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | Janssen Research & Development, LLC | $1,300.00 | 12/26/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A Phase 1b Multicenter, Open-label, Study of JNJ-90014496, an Autologous CD19/CD20 Bi-specific CAR-T Cell Therapy in Adult Participants with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma | No dispute reported | 06/30/2026 | 1175319088 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,316.00 | 12/26/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A Phase 1b Multicenter, Open-label, Study of JNJ-90014496, an Autologous CD19/CD20 Bi-specific CAR-T Cell Therapy in Adult Participants with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma | No dispute reported | 06/30/2026 | 1175319613 |
| Principal investigator 1 | Janssen Research & Development, LLC | $14,436.00 | 12/26/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A Phase 1b Multicenter, Open-label, Study of JNJ-90014496, an Autologous CD19/CD20 Bi-specific CAR-T Cell Therapy in Adult Participants with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma | No dispute reported | 06/30/2026 | 1175322390 |
| Principal investigator 1 | Janssen Research & Development, LLC | $5,750.00 | 12/26/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A Phase 1b Multicenter, Open-label, Study of JNJ-90014496, an Autologous CD19/CD20 Bi-specific CAR-T Cell Therapy in Adult Participants with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma | No dispute reported | 06/30/2026 | 1175323250 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,100.00 | 12/26/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A Phase 1b Multicenter, Open-label, Study of JNJ-90014496, an Autologous CD19/CD20 Bi-specific CAR-T Cell Therapy in Adult Participants with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma | No dispute reported | 06/30/2026 | 1175323368 |
| Principal investigator 1 | Janssen Research & Development, LLC | $4,795.00 | 12/26/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A Phase 1b Multicenter, Open-label, Study of JNJ-90014496, an Autologous CD19/CD20 Bi-specific CAR-T Cell Therapy in Adult Participants with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma | No dispute reported | 06/30/2026 | 1175325102 |
| Principal investigator 1 | Janssen Research & Development, LLC | $4,600.00 | 12/26/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A Phase 1b Multicenter, Open-label, Study of JNJ-90014496, an Autologous CD19/CD20 Bi-specific CAR-T Cell Therapy in Adult Participants with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma | No dispute reported | 06/30/2026 | 1175326452 |
| Principal investigator 1 | Janssen Research & Development, LLC | $3,000.00 | 12/25/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A Phase 1b Multicenter, Open-label, Study of JNJ-90014496, an Autologous CD19/CD20 Bi-specific CAR-T Cell Therapy in Adult Participants with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma | No dispute reported | 06/30/2026 | 1175321443 |
| Principal investigator 1 | Janssen Research & Development, LLC | $67,696.00 | 12/25/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A Phase 1b Multicenter, Open-label, Study of JNJ-90014496, an Autologous CD19/CD20 Bi-specific CAR-T Cell Therapy in Adult Participants with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma | No dispute reported | 06/30/2026 | 1175321709 |
| Principal investigator 1 | PFIZER INC. | $15,000.00 | 12/20/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute LLC | A PHASE 1B OPENLABEL STUDY OF MAPLIRPACEPT IN COMBINATION WITH OTHER ANTICANCER TREATMENTS IN ADULT PARTICIPANTS WITH NONHODGKIN LYMPHOMA | No dispute reported | 06/30/2026 | 1228745491 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $18,701.10 | 12/17/2025 | Covered Recipient Teaching Hospital Swedish Issaquah | Ph 1b of mosunetuzumab combined with lenalidomide in relapsed or refractory follicular lymphoma | No dispute reported | 06/30/2026 | 1211556525 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $13,108.00 | 12/10/2025 | Covered Recipient Teaching Hospital Swedish Issaquah | Ph 1b of mosunetuzumab combined with lenalidomide in relapsed or refractory follicular lymphoma | No dispute reported | 06/30/2026 | 1211556529 |
| Recipient | F. Hoffmann-La Roche AG | $875.67 | 12/09/2025 | Covered Recipient Physician | Patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) preferred fixed-duration treatments with less frequent administrations in the era of novel bispecific antibodies (BsAbs) | No dispute reported | 06/30/2026 | 1211537272 |
| Recipient | F. Hoffmann-La Roche AG | $875.67 | 12/09/2025 | Covered Recipient Physician | Patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) preferred fixed-duration treatments with less frequent administrations in the era of novel bispecific antibodies (BsAbs) | No dispute reported | 06/30/2026 | 1211537275 |
| Recipient | F. Hoffmann-La Roche AG | $1.00 | 12/09/2025 | Covered Recipient Physician | Diverse Preferences for Treatment Options in Relapsed/Refractory (R/R) Follicular Lymphoma (FL): Survey Results from Patients in the United States (US) | No dispute reported | 06/30/2026 | 1211537279 |
| Recipient | F. Hoffmann-La Roche AG | $2,574.25 | 12/09/2025 | Covered Recipient Physician | Diverse Preferences for Treatment Options in Relapsed/Refractory (R/R) Follicular Lymphoma (FL): Survey Results from Patients in the United States (US) | No dispute reported | 06/30/2026 | 1211537283 |
| Principal investigator 1 | Kite Pharma, Inc. | $21,648.78 | 11/21/2025 | Covered Recipient Teaching Hospital Swedish Medical Center | A Phase 2 Multicenter Study Evaluating the Efficacy of KTE-X19 in Subjects with Relapsed/Refractory Mantle Cell Lymphoma (ZUMA 2) | No dispute reported | 06/30/2026 | 1212068571 |
| Principal investigator 1 | Janssen Research & Development, LLC | $3,000.00 | 11/17/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A Phase 1b Multicenter, Open-label, Study of JNJ-90014496, an Autologous CD19/CD20 Bi-specific CAR-T Cell Therapy in Adult Participants with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma | No dispute reported | 06/30/2026 | 1175321656 |
| Principal investigator 1 | Janssen Research & Development, LLC | $3,000.00 | 11/17/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A Phase 1b Multicenter, Open-label, Study of JNJ-90014496, an Autologous CD19/CD20 Bi-specific CAR-T Cell Therapy in Adult Participants with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma | No dispute reported | 06/30/2026 | 1175326185 |
| Principal investigator 1 | Janssen Research & Development, LLC | $7,218.00 | 11/17/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A Phase 1b Multicenter, Open-label, Study of JNJ-90014496, an Autologous CD19/CD20 Bi-specific CAR-T Cell Therapy in Adult Participants with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma | No dispute reported | 06/30/2026 | 1175326350 |
| Principal investigator 1 | Janssen Research & Development, LLC | $10,250.00 | 11/10/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A Phase 1b Multicenter, Open-label, Study of JNJ-90014496, an Autologous CD19/CD20 Bi-specific CAR-T Cell Therapy in Adult Participants with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma | No dispute reported | 06/30/2026 | 1175320655 |
| Principal investigator 1 | Janssen Research & Development, LLC | $3,000.00 | 11/10/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A Phase 1b Multicenter, Open-label, Study of JNJ-90014496, an Autologous CD19/CD20 Bi-specific CAR-T Cell Therapy in Adult Participants with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma | No dispute reported | 06/30/2026 | 1175321507 |
| Principal investigator 1 | PFIZER INC. | $23,678.69 | 11/01/2025 | Covered Recipient Teaching Hospital SWEDISH ISSAQUAH | A PHASE 1B2 OPENLABEL STUDY OF PF07901801 IN COMBINATION WITH GLOFITAMAB AFTER A FIXED SINGLE DOSE OF OBINUTUZUMAB IN PARTICIPANTS WITH RELAPSEDREFRACTORY DIFFUSE LARGE B CELL LYMPHOMA NOT ELIGIBLE FOR STEM CELL TRANSPLANTATION | No dispute reported | 06/30/2026 | 1228728215 |
| Principal investigator 1 | PFIZER INC. | $9,558.22 | 10/31/2025 | Covered Recipient Teaching Hospital SWEDISH ISSAQUAH | A PHASE 1B2 OPENLABEL STUDY OF PF07901801 IN COMBINATION WITH GLOFITAMAB AFTER A FIXED SINGLE DOSE OF OBINUTUZUMAB IN PARTICIPANTS WITH RELAPSEDREFRACTORY DIFFUSE LARGE B CELL LYMPHOMA NOT ELIGIBLE FOR STEM CELL TRANSPLANTATION | No dispute reported | 06/30/2026 | 1228722596 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $634.35 | 10/27/2025 | Non-covered Recipient Entity Scri Oncology Partners | A study of lisocabtagene maraleucel as firstline therapy for primary central nervous system lymphoma in patients who are not eligible for transplant | No dispute reported | 06/30/2026 | 1235993745 |
| Principal investigator 1 | ABBVIE INC. | $3,500.00 | 10/23/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | Study to Evaluate Adverse Events, Change in Disease Activity, and How Intravenously Infused ABBV-291 Moves Through the Body in Adult Participants With Non-Hodgkin s Lymphoma | No dispute reported | 06/30/2026 | 1202518197 |
| Principal investigator 1 | ABBVIE INC. | $5,000.00 | 10/22/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | Study to Evaluate Adverse Events, Change in Disease Activity, and How Intravenously Infused ABBV-291 Moves Through the Body in Adult Participants With Non-Hodgkin s Lymphoma | No dispute reported | 06/30/2026 | 1202518045 |
| Principal investigator 1 | ABBVIE INC. | $14,500.00 | 10/22/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | Study to Evaluate Adverse Events, Change in Disease Activity, and How Intravenously Infused ABBV-291 Moves Through the Body in Adult Participants With Non-Hodgkin s Lymphoma | No dispute reported | 06/30/2026 | 1202518047 |
| Principal investigator 1 | ABBVIE INC. | $6,400.00 | 10/10/2025 | Covered Recipient Teaching Hospital SWEDISH MEDICAL CENTER | Study of Ibrutinib Combined With Venetoclax in Subjects With Mantle Cell Lymphoma (SYMPATICO) | No dispute reported | 06/30/2026 | 1202422212 |
| Principal investigator 1 | Celgene Corporation | $20,000.00 | 10/08/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | An Open-Label, Phase 1/2 Study of JCAR017 in Subjects with Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma | No dispute reported | 06/30/2026 | 1222305642 |
| Principal investigator 1 | Janssen Research & Development, LLC | $26,427.00 | 10/03/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A Phase 1b Multicenter, Open-label, Study of JNJ-90014496, an Autologous CD19/CD20 Bi-specific CAR-T Cell Therapy in Adult Participants with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma | No dispute reported | 06/30/2026 | 1175326610 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $11,750.00 | 09/30/2025 | Non-covered Recipient Entity SCRI ONCOLOGY PARTNERS | A Phase 1b/2 Study of GC012F (AZD0120), a Chimeric Antigen Receptor T-cell (CAR T) Therapy Targeting CD19 and B-cell Maturation Antigen (BCMA) in Subjects With Relapsed/Refractory Multiple Myeloma | No dispute reported | 06/30/2026 | 1185552349 |
| Principal investigator 1 | PFIZER INC. | $101,043.11 | 09/23/2025 | Covered Recipient Teaching Hospital SWEDISH ISSAQUAH | A PHASE 1B2 OPENLABEL STUDY OF PF07901801 IN COMBINATION WITH GLOFITAMAB AFTER A FIXED SINGLE DOSE OF OBINUTUZUMAB IN PARTICIPANTS WITH RELAPSEDREFRACTORY DIFFUSE LARGE B CELL LYMPHOMA NOT ELIGIBLE FOR STEM CELL TRANSPLANTATION | No dispute reported | 06/30/2026 | 1228759240 |
| Principal investigator 1 | PFIZER INC. | $20,637.39 | 09/10/2025 | Covered Recipient Teaching Hospital SWEDISH ISSAQUAH | A PHASE 1B2 OPENLABEL STUDY OF PF07901801 IN COMBINATION WITH GLOFITAMAB AFTER A FIXED SINGLE DOSE OF OBINUTUZUMAB IN PARTICIPANTS WITH RELAPSEDREFRACTORY DIFFUSE LARGE B CELL LYMPHOMA NOT ELIGIBLE FOR STEM CELL TRANSPLANTATION | No dispute reported | 06/30/2026 | 1228754111 |
| Principal investigator 1 | Janssen Research & Development, LLC | $4,856.00 | 08/28/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A Phase 1b Multicenter, Open-label, Study of JNJ-90014496, an Autologous CD19/CD20 Bi-specific CAR-T Cell Therapy in Adult Participants with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma | No dispute reported | 06/30/2026 | 1175320687 |
| Principal investigator 1 | Janssen Research & Development, LLC | $3,000.00 | 08/18/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A Phase 1b Multicenter, Open-label, Study of JNJ-90014496, an Autologous CD19/CD20 Bi-specific CAR-T Cell Therapy in Adult Participants with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma | No dispute reported | 06/30/2026 | 1175320365 |
| Principal investigator 1 | Janssen Research & Development, LLC | $5,750.00 | 08/18/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A Phase 1b Multicenter, Open-label, Study of JNJ-90014496, an Autologous CD19/CD20 Bi-specific CAR-T Cell Therapy in Adult Participants with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma | No dispute reported | 06/30/2026 | 1175321893 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,822.00 | 08/18/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A Phase 1b Multicenter, Open-label, Study of JNJ-90014496, an Autologous CD19/CD20 Bi-specific CAR-T Cell Therapy in Adult Participants with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma | No dispute reported | 06/30/2026 | 1175322699 |
| Principal investigator 1 | PFIZER INC. | $23,679.67 | 08/01/2025 | Covered Recipient Teaching Hospital SWEDISH ISSAQUAH | A PHASE 1B2 OPENLABEL STUDY OF PF07901801 IN COMBINATION WITH GLOFITAMAB AFTER A FIXED SINGLE DOSE OF OBINUTUZUMAB IN PARTICIPANTS WITH RELAPSEDREFRACTORY DIFFUSE LARGE B CELL LYMPHOMA NOT ELIGIBLE FOR STEM CELL TRANSPLANTATION | No dispute reported | 06/30/2026 | 1228767878 |
| Principal investigator 1 | Janssen Research & Development, LLC | $7,218.00 | 07/28/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A Phase 1b Multicenter, Open-label, Study of JNJ-90014496, an Autologous CD19/CD20 Bi-specific CAR-T Cell Therapy in Adult Participants with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma | No dispute reported | 06/30/2026 | 1175319081 |
| Principal investigator 1 | Janssen Research & Development, LLC | $3,000.00 | 07/28/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A Phase 1b Multicenter, Open-label, Study of JNJ-90014496, an Autologous CD19/CD20 Bi-specific CAR-T Cell Therapy in Adult Participants with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma | No dispute reported | 06/30/2026 | 1175323124 |
| Principal investigator 1 | Kite Pharma, Inc. | $1,300.00 | 07/28/2025 | Covered Recipient Teaching Hospital Swedish Medical Center | A Phase 3, Randomized, Open-Label Study Evaluating the Efficacy of Axicabtagene Ciloleucel versus Standard of Care Therapy in Subjects with Relapsed/Refractory Diffuse Large B Cell Lymphoma (ZUMA 7) | No dispute reported | 06/30/2026 | 1212068693 |
| Principal investigator 1 | Janssen Research & Development, LLC | $3,000.00 | 07/17/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A Phase 1b Multicenter, Open-label, Study of JNJ-90014496, an Autologous CD19/CD20 Bi-specific CAR-T Cell Therapy in Adult Participants with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma | No dispute reported | 06/30/2026 | 1175321922 |
| Principal investigator 1 | PFIZER INC. | $14,024.93 | 07/12/2025 | Covered Recipient Teaching Hospital SWEDISH ISSAQUAH | A PHASE 1B2 OPENLABEL STUDY OF PF07901801 IN COMBINATION WITH GLOFITAMAB AFTER A FIXED SINGLE DOSE OF OBINUTUZUMAB IN PARTICIPANTS WITH RELAPSEDREFRACTORY DIFFUSE LARGE B CELL LYMPHOMA NOT ELIGIBLE FOR STEM CELL TRANSPLANTATION | No dispute reported | 06/30/2026 | 1228765285 |
| Principal investigator 1 | Janssen Research & Development, LLC | $3,210.00 | 07/10/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A Phase 1b Multicenter, Open-label, Study of JNJ-90014496, an Autologous CD19/CD20 Bi-specific CAR-T Cell Therapy in Adult Participants with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma | No dispute reported | 06/30/2026 | 1175321036 |
| Principal investigator 1 | Janssen Research & Development, LLC | $17,061.00 | 07/07/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A Phase 1b Multicenter, Open-label, Study of JNJ-90014496, an Autologous CD19/CD20 Bi-specific CAR-T Cell Therapy in Adult Participants with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma | No dispute reported | 06/30/2026 | 1175323086 |
| Principal investigator 1 | PFIZER INC. | $23,747.63 | 06/25/2025 | Covered Recipient Teaching Hospital SWEDISH ISSAQUAH | A PHASE 1B2 OPENLABEL STUDY OF PF07901801 IN COMBINATION WITH GLOFITAMAB AFTER A FIXED SINGLE DOSE OF OBINUTUZUMAB IN PARTICIPANTS WITH RELAPSEDREFRACTORY DIFFUSE LARGE B CELL LYMPHOMA NOT ELIGIBLE FOR STEM CELL TRANSPLANTATION | No dispute reported | 06/30/2026 | 1228777283 |
| Principal investigator 1 | PFIZER INC. | $47,686.32 | 05/29/2025 | Covered Recipient Teaching Hospital SWEDISH ISSAQUAH | A PHASE 1B2 OPENLABEL STUDY OF PF07901801 IN COMBINATION WITH GLOFITAMAB AFTER A FIXED SINGLE DOSE OF OBINUTUZUMAB IN PARTICIPANTS WITH RELAPSEDREFRACTORY DIFFUSE LARGE B CELL LYMPHOMA NOT ELIGIBLE FOR STEM CELL TRANSPLANTATION | No dispute reported | 06/30/2026 | 1228764401 |
| Principal investigator 1 | Janssen Research & Development, LLC | $3,938.00 | 05/23/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A Phase 1b Multicenter, Open-label, Study of JNJ-90014496, an Autologous CD19/CD20 Bi-specific CAR-T Cell Therapy in Adult Participants with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma | No dispute reported | 06/30/2026 | 1175318991 |
| Principal investigator 1 | Janssen Research & Development, LLC | $3,000.00 | 05/23/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A Phase 1b Multicenter, Open-label, Study of JNJ-90014496, an Autologous CD19/CD20 Bi-specific CAR-T Cell Therapy in Adult Participants with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma | No dispute reported | 06/30/2026 | 1175325035 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,500.00 | 05/23/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A Phase 1b Multicenter, Open-label, Study of JNJ-90014496, an Autologous CD19/CD20 Bi-specific CAR-T Cell Therapy in Adult Participants with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma | No dispute reported | 06/30/2026 | 1175325834 |
| Principal investigator 1 | PFIZER INC. | $39,070.15 | 05/03/2025 | Covered Recipient Teaching Hospital SWEDISH ISSAQUAH | A PHASE 1B2 OPENLABEL STUDY OF PF07901801 IN COMBINATION WITH GLOFITAMAB AFTER A FIXED SINGLE DOSE OF OBINUTUZUMAB IN PARTICIPANTS WITH RELAPSEDREFRACTORY DIFFUSE LARGE B CELL LYMPHOMA NOT ELIGIBLE FOR STEM CELL TRANSPLANTATION | No dispute reported | 06/30/2026 | 1228723392 |
| Principal investigator 1 | Janssen Research & Development, LLC | $16,900.00 | 04/11/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A Phase 1b Multicenter, Open-label, Study of JNJ-90014496, an Autologous CD19/CD20 Bi-specific CAR-T Cell Therapy in Adult Participants with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma | No dispute reported | 06/30/2026 | 1175324122 |
| Principal investigator 1 | Janssen Research & Development, LLC | $3,000.00 | 04/11/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A Phase 1b Multicenter, Open-label, Study of JNJ-90014496, an Autologous CD19/CD20 Bi-specific CAR-T Cell Therapy in Adult Participants with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma | No dispute reported | 06/30/2026 | 1175324638 |
| Principal investigator 1 | Janssen Research & Development, LLC | $500.00 | 04/11/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A Phase 1b Multicenter, Open-label, Study of JNJ-90014496, an Autologous CD19/CD20 Bi-specific CAR-T Cell Therapy in Adult Participants with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma | No dispute reported | 06/30/2026 | 1175325971 |
| Principal investigator 1 | AstraZeneca UK Limited | $4,000.00 | 03/26/2025 | Non-covered Recipient Entity SWEDISH HEALTH SERVICES | a modular phase second,open label,multicentre study to assess efficacy and safety as monotherapy or in combination with antia cancer agents in patients with relapsed refractory peripheral t cell lymphoma or classical hodgkin lymphoma | No dispute reported | 06/30/2026 | 1185552351 |
| Principal investigator 1 | PFIZER INC. | $43,964.48 | 03/21/2025 | Covered Recipient Teaching Hospital SWEDISH ISSAQUAH | A PHASE 1B2 OPENLABEL STUDY OF PF07901801 IN COMBINATION WITH GLOFITAMAB AFTER A FIXED SINGLE DOSE OF OBINUTUZUMAB IN PARTICIPANTS WITH RELAPSEDREFRACTORY DIFFUSE LARGE B CELL LYMPHOMA NOT ELIGIBLE FOR STEM CELL TRANSPLANTATION | No dispute reported | 06/30/2026 | 1228787324 |
| Principal investigator 1 | Kite Pharma, Inc. | $12,403.00 | 03/18/2025 | Covered Recipient Teaching Hospital Swedish Medical Center | A Phase 2 Multicenter Study Evaluating the Efficacy of KTE-X19 in Subjects with Relapsed/Refractory Mantle Cell Lymphoma (ZUMA 2) | No dispute reported | 06/30/2026 | 1212068564 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $4,631.00 | 03/05/2025 | Covered Recipient Teaching Hospital Swedish Issaquah | Ph 1b of mosunetuzumab combined with lenalidomide in relapsed or refractory follicular lymphoma | No dispute reported | 06/30/2026 | 1211556449 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $6,339.00 | 03/05/2025 | Covered Recipient Teaching Hospital Swedish Issaquah | Ph 1b of mosunetuzumab combined with lenalidomide in relapsed or refractory follicular lymphoma | No dispute reported | 06/30/2026 | 1211556457 |
| Principal investigator 1 | PFIZER INC. | $3,511.59 | 03/01/2025 | Covered Recipient Teaching Hospital SWEDISH ISSAQUAH | A PHASE 1B2 OPENLABEL STUDY OF PF07901801 IN COMBINATION WITH GLOFITAMAB AFTER A FIXED SINGLE DOSE OF OBINUTUZUMAB IN PARTICIPANTS WITH RELAPSEDREFRACTORY DIFFUSE LARGE B CELL LYMPHOMA NOT ELIGIBLE FOR STEM CELL TRANSPLANTATION | No dispute reported | 06/30/2026 | 1228788341 |
| Principal investigator 1 | Eli Lilly and Company | $335,136.85 | 02/07/2025 | Covered Recipient Teaching Hospital SWEDISH ISSAQUAH | A PHASE 1/2 STUDY OF ORAL LOXO-305 IN PATIENTS WITH PREVIOUSLY TREATED CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA (CLL/SLL) OR NON-HODGKIN LYMPHOMA (NHL) | No dispute reported | 06/30/2026 | 1187872353 |
| Principal investigator 1 | Eli Lilly and Company | $2,234.64 | 01/27/2025 | Covered Recipient Teaching Hospital SWEDISH ISSAQUAH | A PHASE 1/2 STUDY OF ORAL LOXO-305 IN PATIENTS WITH PREVIOUSLY TREATED CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA (CLL/SLL) OR NON-HODGKIN LYMPHOMA (NHL) | No dispute reported | 06/30/2026 | 1187877409 |
| Principal investigator 1 | Kite Pharma, Inc. | $6,783.24 | 01/22/2025 | Covered Recipient Teaching Hospital Swedish Medical Center | A Phase 3, Randomized, Open-Label Study Evaluating the Efficacy of Axicabtagene Ciloleucel versus Standard of Care Therapy in Subjects with Relapsed/Refractory Diffuse Large B Cell Lymphoma (ZUMA 7) | No dispute reported | 06/30/2026 | 1212068686 |
| Principal investigator 1 | PFIZER INC. | $5,636.39 | 01/14/2025 | Covered Recipient Teaching Hospital SWEDISH ISSAQUAH | A PHASE 1B2 OPENLABEL STUDY OF PF07901801 IN COMBINATION WITH GLOFITAMAB AFTER A FIXED SINGLE DOSE OF OBINUTUZUMAB IN PARTICIPANTS WITH RELAPSEDREFRACTORY DIFFUSE LARGE B CELL LYMPHOMA NOT ELIGIBLE FOR STEM CELL TRANSPLANTATION | No dispute reported | 06/30/2026 | 1228799869 |